340 related articles for article (PubMed ID: 31232607)
1. Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren H
Expert Opin Ther Targets; 2019 Aug; 23(8):679-693. PubMed ID: 31232607
[No Abstract] [Full Text] [Related]
2. TGF-beta: a master immune regulator.
Larson C; Oronsky B; Carter CA; Oronsky A; Knox SJ; Sher D; Reid TR
Expert Opin Ther Targets; 2020 May; 24(5):427-438. PubMed ID: 32228232
[No Abstract] [Full Text] [Related]
3. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.
van den Bulk J; de Miranda NFCC; Ten Dijke P
Clin Sci (Lond); 2021 Jan; 135(1):35-52. PubMed ID: 33399850
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy via targeted TGF-β signalling blockade in T
Li S; Liu M; Do MH; Chou C; Stamatiades EG; Nixon BG; Shi W; Zhang X; Li P; Gao S; Capistrano KJ; Xu H; Cheung NV; Li MO
Nature; 2020 Nov; 587(7832):121-125. PubMed ID: 33087933
[TBL] [Abstract][Full Text] [Related]
6. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta-based immunotherapy for cancer: breaching the tumor firewall.
Shah AH; Lee C
Prostate; 2000 Oct; 45(2):167-72. PubMed ID: 11027416
[TBL] [Abstract][Full Text] [Related]
8. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.
Yi M; Li T; Niu M; Wu Y; Zhao Z; Wu K
Front Immunol; 2022; 13():1061394. PubMed ID: 36601124
[TBL] [Abstract][Full Text] [Related]
9. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
10. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
Bialkowski L; Van der Jeught K; Bevers S; Tjok Joe P; Renmans D; Heirman C; Aerts JL; Thielemans K
Int J Cancer; 2018 Aug; 143(3):686-698. PubMed ID: 29464699
[TBL] [Abstract][Full Text] [Related]
12. Effects of TGF-beta on the immune system: implications for cancer immunotherapy.
de Visser KE; Kast WM
Leukemia; 1999 Aug; 13(8):1188-99. PubMed ID: 10450746
[TBL] [Abstract][Full Text] [Related]
13. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
Takasaka N; Seed RI; Cormier A; Bondesson AJ; Lou J; Elattma A; Ito S; Yanagisawa H; Hashimoto M; Ma R; Levine MD; Publicover J; Potts R; Jespersen JM; Campbell MG; Conrad F; Marks JD; Cheng Y; Baron JL; Nishimura SL
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333313
[TBL] [Abstract][Full Text] [Related]
14. Transforming Growth Factor-β Signaling in Immunity and Cancer.
Batlle E; Massagué J
Immunity; 2019 Apr; 50(4):924-940. PubMed ID: 30995507
[TBL] [Abstract][Full Text] [Related]
15. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
16. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy.
Jiang J; Zhang Y; Peng K; Wang Q; Hong X; Li H; Fan G; Zhang Z; Gong T; Sun X
Acta Biomater; 2017 Oct; 61():114-123. PubMed ID: 28483693
[TBL] [Abstract][Full Text] [Related]
17. Garp as a therapeutic target for modulation of T regulatory cell function.
Shevach EM
Expert Opin Ther Targets; 2017 Feb; 21(2):191-200. PubMed ID: 28001437
[TBL] [Abstract][Full Text] [Related]
18. The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis.
Chen B; Mu C; Zhang Z; He X; Liu X
Front Immunol; 2022; 13():891268. PubMed ID: 35720407
[TBL] [Abstract][Full Text] [Related]
19. Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C; van Ginkel JQ; Kinderman P; Sluijter M; Griffioen L; Labrie C; van den Wollenberg DJM; Hoeben RC; van der Burg SH; Ten Dijke P; Hawinkels LJAC; van Hall T; van Montfoort N
Cancer Res Commun; 2023 Feb; 3(2):325-337. PubMed ID: 36860656
[TBL] [Abstract][Full Text] [Related]
20. Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy.
Zhao H; Wei J; Sun J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107101. PubMed ID: 33099067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
